Remdesivir-induced bradycardia in a 26-year-old patient with COVID-19: a case report

PURPOSE: Remdesivir is the first line hospital treatment of the SARS-CoV-2 infection. Despite its widespread use during COVID-19 pandemic, a limited number of data, also conflicting, are available about the frequency of cardiological side-effects. Additionally, identification of patients who belong...

Descripción completa

Detalles Bibliográficos
Autores principales: Guziejko, Katarzyna, Talalaj, Jaroslaw, Chorazy, Monika, Groth, Monika, Moniuszko-Malinowska, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196856/
https://www.ncbi.nlm.nih.gov/pubmed/35701724
http://dx.doi.org/10.1007/s15010-022-01854-3
Descripción
Sumario:PURPOSE: Remdesivir is the first line hospital treatment of the SARS-CoV-2 infection. Despite its widespread use during COVID-19 pandemic, a limited number of data, also conflicting, are available about the frequency of cardiological side-effects. Additionally, identification of patients who belong to the risk groups for cardiovascular complications of antiviral treatment is difficult. CASE DESCRIPTION: Case description We present a case of a 26 year old patient, a soldier with COVID-19 and no comorbidities, who developed marked sinus bradycardia during remdesivir therapy. The bradycardia resolved few days after the end of antiviral treatment. CONCLUSION: Our case emphasizes the key importance of the correct monitoring of patients receiving remdesivir, even those who do not have pre-existing heart conditions.

Ejemplares similares